Overview
Program Overview
The theme of this year’s Annual Meeting is Toward a Well-Being Future in which Each and Every One of Us Has ‘Ikigai’. We have seen a recent increase in the number of Japanese words that are accepted around the world, and “Ikigai” has been added to this list for several years. Recent studies have shown that people who have a higher sense of purpose in life, those who feel that what is important in life makes life worth living, tend to have a lower risk of death and cardiovascular disease and have a longer healthy life expectancy. In recent years, attention has also focused on “well-being,” a state of complete physical, mental, and social well-being; the Growth Strategy Action Plan has set the goal of realizing a society in which people can experience “well-being” in Japan.
In this context, healthcare must be designed to help people remain not only physically and mentally healthy, but also socially and economically well and fulfilled. In the past, the mainstream of pharmaceutical and medical device industries has been the development of products to treat diseases. More comprehensive healthcare is required to create a world where people can live and realize “well being” by connecting with society despite living with their illnesses. This healthcare design change must create a new drug discovery ecosystem different from the past.
What people find as “Ikigai” in their life is unique to everyone, and each person has his/her own “well-being.” Therefore, to achieve a society where each person can realize his/her own “well-being” with his/her own “Ikigai,” we must bring together people from all walks of life in industry, government, academia, and the private sector – people from inside and outside of the pharmaceutical industry, and people from Asia and other countries outside of Japan.
We hope that this year’s DIA Japan Annual Meeting will provide the forum where people from all walks of life, organizations, roles, industries, and countries, can gather to discuss the co-creation of a society in which each person can realize their own unique “well-being” by creating a place where everyone can freely discuss their own thoughts without excluding or being excluded from anyone else’s ideas.
Program Committee
-
Kazuo Nakamura, PhD Representative Director, Chairman and CEO
CMIC HOLDINGS, Japan -
Noriaki Nagao, MPharm, PMP Pharmaceutical Division,Clinical Development Dept.
JAPAN TOBACCO INC., Japan -
Eri Sekine Executive Vice President
CMIC Group, Japan -
Tomoko Kondo, PhD, RPh Professor, Division of Translational Medicine
Kagoshima University, Japan -
TOMONORI ABE, MSc Associate Manager
Linical Co., Ltd., Japan -
Kasumi Daidoji, PhD, RPh Associate Director, Clinical Planning & Development Dept., Medical Headquarters
Eisai Company, Ltd., Japan -
Mayu Fujita Senior Reviewer, Office of Pharmacovigilance l, office of new Drug l
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Fukagawa Emiko Clinical Research Center in Hiroshima/Department of Pharmaceutical Services
Hiroshima University Hospital, Japan -
Jun Hasegawa Medical solution Partner
M3, Inc., Japan -
Kanji Hirai, RPh Director, Regulatory Policy & Intelligence, Regulatory Affair Area, Japan Dvlpmt
MSD K.K., Japan -
Yuki Kai, MBA Clinical Strategy and Resource Management Department, Clinical Development Divis
Chugai Pharmaceutical Co., Ltd.,, Japan -
Yusuke Kajimoto Senior Scientist, Scientific Affairs
MSD K.K., Japan -
Keiko Katsui, PhD Group of Social Co-Creation
Japan Agency for Medical Research and Development (AMED), Japan -
Atsushi Kitamura, MS Director, GCP Quality Japan
Pfizer R&D Japan G.K., Japan -
Reina Kodera Manager, Healthcare Industries Division
Ministry of Economy, Trade and Industry (METI), Japan -
Yuko Kojima, RPh Sr. Executive Director
Eli Lilly Japan K.K., Japan -
Naoki Kotani, MSc Pharmaceutical Science Dept.
Chugai Pharmaceutical Co., Ltd., Japan -
Junpei Kozaki Senior Manager, Clinical Development
PAREXEL International Inc., Japan -
Takeshi Mikami Sr. Statstical Prgrammer Analysit, SP&A
Janssen: Pharmaceutical Companies of Johnson & Johnson, Japan -
Yuko Mitobe Representative/Employees with cancer
Cancer Osyaberi Cafe/Akihabara Social Insurance and Labor Consultant Corporation, Japan -
Akira Nakanishi
Century Medical,Inc., Japan -
Yukiko Nishimura, PhD, MSc Director
Advocacy Service for Rare and Intractable Diseases, Japan -
Fumitaka Noji Asscociate Director, Clinical Operations (Therapeutics and Oncology)
Moderna Japan Co., Ltd., Japan -
Yasuharu Shibata, MSc Head of Clinical Data Management, Cliinical Data Management
MSD K.K., Japan -
Mikiko Shitara Senior Manager, Regulatory Affairs Dept.
Alexionpharma GK, Japan -
Sho Suzuki Deputy Review Director, Office of New Drug IV
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Satoshi Suzuki Manager, Project Management Group, Japan Portfolio & Project Management
Pfizer R&D Japan G.K., Japan -
Keisuke Suzuki, PhD Director, Innovation Center for Translational Research
National Center for Geriatrics and Gerontology, Japan -
Yoshiko Takagi Center for Clinical Research
Shinshu University Hospital, Japan -
Mitsutoshi Toda, MBA Senior Lead, CRM Medical Franchise Dept. Japan Medical Division
Novartis Pharma K.K., Japan -
Masashi Uchida Senior Manager, Clinical Trial Monitoring Group
Bristol-Myers Squibb K.K., Japan -
Manami Yoshida, DVM Associate Director, Medical Affairs – HIV & COVID-19
Gilead Sciences K.K., Japan -
Haruko Yamamoto, MD, PhD Executive Director
National Cerebral and Cardiovascular Center, Japan -
Junichi Nishino, MSc, RPh Head, Regulatory Affairs Department
Otsuka Pharmaceutical Co., Ltd., Japan -
Goshi Ozawa, MS Representative Director & President, Japan / R&D Head
Juniper Therapeutix K.K., Japan -
Yukihiro Matsuda, MSc Director, Clinical Delivery
ICON Clinical Research GK, Japan -
Masaru Iwasaki, MD, PhD Vice President, Head of Center for Advancing Clinical Research (CACR)
University of Yamanashi, Japan -
Keiko Oishi, MSc President and COO
CMIC Group, Japan -
Hiroshi Kosaku, MSc Senior Corporate Officer, Non-clinical CRO Business, Bio-CDMO Business
CMIC HOLDINGS, Japan -
Hironobu Saito, PhD Specially Appointed Professor
Tottori University, Chromosome Egineering Research Center, Japan -
Yil-Seob Lee, MD, PhD Professor, Dept of Clinical Pharmacology
CHA Global clinical research center, CHA University, Korea, Republic of -
Xiaojun (Wendy) Yan, MD, MBA Senior Vice President, Chief Regulatory Officer
BeiGene (Beijing) Co., Ltd., China -
Karen Chu, PharmD CEO
Harvest Integrated Research Organization (HiRO), Taiwan -
Jing Ping Yeo, PhD Global Head, Project Operations & Head, Transformation
George Clinical, Singapore -
Steve Engen CEO
Renexes LLC, United States -
Koichi GOTO Deputy Manager
CM Plus Corporation, Japan -
Mana Osano Member, Regulatory Affaris Department
Otsuka Pharmaceutical Co., Ltd., Japan -
Maki Yoro Office of Safety I
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Shogo Nakamori, MBA, MSc, RPh Senior Vice President & Managing Director, DIA Japan, Korea, and Singapore
DIA, Japan
Have an account?